Haemonetics (Haemonetics) Interest Expense : $-9 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Haemonetics's interest expense for the three months ended in Dec. 2023 was $ -2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Haemonetics's Operating Income for the three months ended in Dec. 2023 was $ 46 Mil. Haemonetics's Interest Expense for the three months ended in Dec. 2023 was $ -2 Mil. Haemonetics's Interest Coverage for the quarter that ended in Dec. 2023 was 23.59. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Haemonetics Interest Expense Historical Data

The historical data trend for Haemonetics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Interest Expense Chart

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-9.91

-16.20

-16.83

-17.12

-14.63

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.06	-2.63	-2.07	-2.47	-1.95

Haemonetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9 Mil.

Haemonetics (NYSE:HAE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Haemonetics's Interest Expense for the three months ended in Dec. 2023 was $-2 Mil. Its Operating Income for the three months ended in Dec. 2023 was $46 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $857 Mil.

Haemonetics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	45.978	/	-1.949
	=	23.59

The higher the ratio, the stronger the company's financial strength is.

Haemonetics (Haemonetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

HAZ:Germany

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Executives

Stewart W Strong	officer: President, Global Hospital	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni	officer: EVP, Chief Technology Officer	HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant	director	2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens	officer: EVP, Global Manufacturing	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil	officer: EVP and General Counsel	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell	officer: VP, Chief Accounting Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin	officer: President, Global Plasma & BC	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller	officer: SVP, Human Resources	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll	director	PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein	officer: VP, Corporate Controller	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon,	director, officer: President & CEO	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca	officer: EVP, Chief Financial Officer	C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr.	officer: EVP, Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson	director	16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277